BIOTECanada celebrates the bilateral agreement between the Government of Canada and the province of Quebec, completing a pan-Canadian commitment to the national strategy for drugs for rare diseases. This milestone marks a united effort across all provinces and territories to improve access to new solutions for Canadian rare disease patients.
From early stage biotechs to large multinational companies, BIOTECanada members drive discovery and delivery of medicines that change the lives of patients with rare diseases. We will continue to work actively and collaboratively with federal partners to ensure Canadian rare disease patients remain at the forefront of informed decisions regarding these vital new therapies.
To view all the bilateral agreements, visit: https://www.canada.ca/en/health-canada/corporate/transparency/health-agreements/shared-health-priorities/drugs-for-rare-diseases-bilateral-agreements.html